A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)
CONCLUSION: Rucaparib demonstrated acceptable toxicity and efficacy signal as an ADT-sparing approach in patients with biochemically recurrent nonmetastatic prostate cancer. It is currently challenging to understand the optimal value of systemic therapy in this disease setting due to the rapidly changing standard of care. Additionally, there are relatively few patients with BRCAness who present with nonmetastatic hormone-sensitive prostate cancer (ClinicalTrials.gov Identifier: NCT03533946).PMID:38452035 | DOI:10.1093/oncolo/oyae030
Source: The Oncologist - Category: Cancer & Oncology Authors: Kamal Kant Sahu Haoran Li Vinay Mathew Thomas Mallory Benson Ken Boucher Sumati Gupta Manish Kohli Umang Swami Neeraj Agarwal Benjamin L Maughan Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Gastroschisis Repair | Genetics | Hormones | PET Scan | Prostate Cancer | Psychology | Study | Toxicology